#Blood Screening Market size

[latestmarketresearchnews]

Blood Screening Market Size, Share & Trends Analysis Report By 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market's rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible infections. This growth is further fueled by advancements in technology, particularly in automation and molecular platforms, which enhance the accuracy and efficiency of blood screening processes. Additionally, the rising prevalence of infectious diseases, combined with government initiatives aimed at promoting blood safety, is contributing to the market's upward trajectory. Growing public awareness about the importance of safe blood transfusions also plays a key role in market growth.

Blood screening is a critical medical procedure that involves analyzing blood samples to detect various health conditions and abnormalities. It provides vital insights into an individual's health, allowing for the early detection, prevention, and management of diseases. The screening process typically involves evaluating blood cell counts, identifying infectious agents like viruses and bacteria, and measuring levels of chemicals such as cholesterol and glucose. The significance of blood screening lies in its ability to help healthcare professionals identify potential health problems before symptoms appear. This is crucial in diagnosing conditions like anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological advancements continue to improve the precision and efficiency of blood screening methods. At the same time, increasing awareness about the importance of early disease detection promotes the adoption of preventive healthcare measures. Another contributing factor to the market's growth is the aging global population, which is associated with a higher prevalence of diseases that require blood screening. Rising healthcare expenditures around the world also support the adoption of advanced technologies and services in the blood screening field. Together, these factors drive the ongoing growth and evolution of the blood screening market, highlighting its essential role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Product Segmentation Insights:

In 2024, reagents led the blood screening market, accounting for the largest revenue share of 73.4%. Reagents are critical components in diagnostic tests, providing the chemical, biological, or immunological substances required to trigger specific reactions that yield accurate test results. The growing demand for highly specific and precise blood analyses has driven the development of innovative reagent formulations that enhance the performance of diagnostic tests. Reagents are also cost-effective, making them widely accessible, which contributes to their dominant market position.

The instruments segment is expected to experience the fastest growth, with a projected CAGR of 10.8% over the forecast period. This growth is attributed to technological advancements and the increasing demand for reliable diagnostic solutions. Modern blood screening instruments are designed to improve both accuracy and efficiency, addressing the need for rapid diagnostics in healthcare settings. Innovations such as high-throughput analyzers and point-of-care testing devices have improved the usability and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, continuous technological development is expected to drive sustained growth in this segment. Healthcare providers are increasingly seeking dependable and efficient tools for blood analysis, and the advancements in instruments are expected to meet these evolving needs.

In summary, the global blood screening market is poised for strong growth due to factors such as increasing blood donations, technological innovations, rising healthcare expenditures, and greater public awareness. The market will continue to evolve, driven by a combination of product developments in reagents and instruments, along with a growing focus on preventive healthcare and early disease detection.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Blood Screening Industry Size & Share | Statistics Report 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market's rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible infections. This growth is further fueled by advancements in technology, particularly in automation and molecular platforms, which enhance the accuracy and efficiency of blood screening processes. Additionally, the rising prevalence of infectious diseases, combined with government initiatives aimed at promoting blood safety, is contributing to the market's upward trajectory. Growing public awareness about the importance of safe blood transfusions also plays a key role in market growth.

Blood screening is a critical medical procedure that involves analyzing blood samples to detect various health conditions and abnormalities. It provides vital insights into an individual's health, allowing for the early detection, prevention, and management of diseases. The screening process typically involves evaluating blood cell counts, identifying infectious agents like viruses and bacteria, and measuring levels of chemicals such as cholesterol and glucose. The significance of blood screening lies in its ability to help healthcare professionals identify potential health problems before symptoms appear. This is crucial in diagnosing conditions like anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological advancements continue to improve the precision and efficiency of blood screening methods. At the same time, increasing awareness about the importance of early disease detection promotes the adoption of preventive healthcare measures. Another contributing factor to the market's growth is the aging global population, which is associated with a higher prevalence of diseases that require blood screening. Rising healthcare expenditures around the world also support the adoption of advanced technologies and services in the blood screening field. Together, these factors drive the ongoing growth and evolution of the blood screening market, highlighting its essential role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Product Segmentation Insights:

In 2024, reagents led the blood screening market, accounting for the largest revenue share of 73.4%. Reagents are critical components in diagnostic tests, providing the chemical, biological, or immunological substances required to trigger specific reactions that yield accurate test results. The growing demand for highly specific and precise blood analyses has driven the development of innovative reagent formulations that enhance the performance of diagnostic tests. Reagents are also cost-effective, making them widely accessible, which contributes to their dominant market position.

The instruments segment is expected to experience the fastest growth, with a projected CAGR of 10.8% over the forecast period. This growth is attributed to technological advancements and the increasing demand for reliable diagnostic solutions. Modern blood screening instruments are designed to improve both accuracy and efficiency, addressing the need for rapid diagnostics in healthcare settings. Innovations such as high-throughput analyzers and point-of-care testing devices have improved the usability and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, continuous technological development is expected to drive sustained growth in this segment. Healthcare providers are increasingly seeking dependable and efficient tools for blood analysis, and the advancements in instruments are expected to meet these evolving needs.

In summary, the global blood screening market is poised for strong growth due to factors such as increasing blood donations, technological innovations, rising healthcare expenditures, and greater public awareness. The market will continue to evolve, driven by a combination of product developments in reagents and instruments, along with a growing focus on preventive healthcare and early disease detection.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[marketresearchreportinsight]

Blood Screening Industry Analysis And Segment Forecast till 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market’s rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible…

[industrynewsupdates]

Blood Screening Market Outlook and Forecast Report, 2030

The global blood screening market is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Detailed Segmentation:

Product Insights

On the basis of product, the market is segmented into instruments and reagents. The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period owing to higher accuracy and specificity in detecting the presence and type of various elements in a small sample would drive the market.

Technology Insights

On the basis of technology, the market is segmented into nucleic acid amplification tests, ELISA, CLIA, EIA, NGS, and western blotting. The NAT segment accounted for the largest revenue share of 41.8% in 2022, owing to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid earlier than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV. According to the WHO, HIV has claimed 40.1 million lives till now and remains a global health concern with the current transmission in all countries where 1.5 million people attained HIV in 2021.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period. The U.S. leads the market due to the local presence of leading players such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global electron microscopes market size was valued at USD 5.05 billion in 2023 and is projected to grow at a CAGR of 8.1% from 2024 to 2030.

• The global ambient assisted living market size was valued at USD 7.36 billion in 2023 and is projected to grow at a CAGR of 26.8% from 2024 to 2030. . 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023,Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

The report "Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028", is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

[aadeshmmr]

The examination of the COVID-19 lock-down's effects on market leaders', followers', and disruptors' revenue is included in the research.

[nvuy]

nuvy. nuvy have you heard of the boothill leaks.

YES i did *salutes*

boothill story leaks under cut;

girl dad girl dad

soooo what about boothill falling in love with a single parent with a daughter hmm hmm

like god if he doesn’t just accidently run into the kid and she squeals over him because “hey!! cool robot man!!” and you chase her down and apologise.

he freezes, because your daughter looks so much like his did.

same hair colour, same eye colour, same energy that he could barely keep up with, just learning to walk on two feet properly and string together words to form simple sentences.

it absolutely destroys him. in the worst and best way possible. especially since your daughter practically develops an admiration for him on the spot, begs to be carried, and you’re confused because “sweetie, you shouldn’t be talking to strangers.”

like like.,,,, example……..

Something small and warm wraps around his hand and Boothill glances up quickly from his lap.

There was a little girl searching for his fingers, barely three years old by the looks of it. Pretty tresses of black hair flowing in the wind near the shoreline, sniffling and barely standing on short wobbly legs.

“I need help,” she hiccups, and Boothill melts on the spot. So small and helpless, like a baby bird away from its mother’s nest. “I can’t find my–”

And of course, he stands up, dusts off his pants, and offers her his hand. He guides her away from the beach back towards the market where crowds of people swarm the stalls.

It’s nighttime, cold, and definitely no place for a little girl to be by herself.

“What’s your parents look like, princess?”

He busies himself searching for any targets that would make sense given the girl’s prattling of your appearance down to the colour of your shoes—“White. Like mine.” Hers light up purple with each step she takes—too many faces, too many people.

He stands to give up when he hears somebody frantically running around like a lunatic to every single store, asking if they’ve seen a little girl with light up sneakers wandering about.

“Calm down. I’m sure she’s around here somewhere,” he heard one of the assistants try.

Another shopkeeper offers a pitiful frown and shakes their head.

Boothill nudges the girl, squeezing her small hand in his, careful of his strength around fragile bones. “Is that them?”

She quickly wipes the tears from her face. She then nods and takes off into a sprint to lunge at you, still sobbing when she wraps her arms around your leg.

You sigh in relief and scoop her up into your arms.

Boothill then has an entire conundrum in the middle of the market square. For one, your daughter is waving him over with a smile on her face. Two, you looked like you were about two seconds away from passing out in shock. Your clothes are askew, hair a mess, face flushed and yet simultaneously drained of blood.

He steps closer anyway, though hesitantly. He can’t say no to the little thing whose grin has now grown double the size of her face.

“This is the man that helped me,” she explained softly to you, pointing at him with a small finger.

You scanned him over.

For a moment, he thought you were going to turn around and book it in the other direction. A random ‘robot man’ in the centre of the town square was probably the least most inviting thing he could’ve been. Not to mention he had been sitting at the docks for so long staring out into the water he knew his hair had been tossed wildly from the wind.

Not that you appeared anymore put together.

Instead, you grab his face with a free hand and kiss him on the cheek.

“Thank you,” you whispered hoarsely.

He almost damn near blue screens. The words ‘anything for you’ fight to come forth out of his throat.

Instead, he lets out a garbled noise before he clears his throat. “Of course. Couldn’t let the little princess run too far.” He teased your daughter with a tap to her nose.

She grabs his finger and presses the pads of her own across the metal rivets and joints like she’s studying them curiously.

Your daughter stared up at you with giant puppy eyes, still holding his hand. “Can we keep him?”

It was your turn to make a weird noise, spluttering with your face heating up. “You can’t keep people.”

All the while, Boothill was staring at you as you chastised her with hot cheeks.

No spouse by the looks of it—nor had the little princess mentioned somebody else. He knew kids liked to ramble on about their parents.

Well, his daughter did. Something cold and metallic turned in his stomach. She used to think her dad was a hero.

He wondered if she still would.

No ring on your finger. Adoration was such a gentle expression on your face, and the way you held her so firmly, yet so delicately, said it all.

Oh, if he wasn’t completely head over heels from the very beginning.

the angst potential. The angst potential. Theeee angst potential. i’m gritting my teeth.

i’m going insan e

[roshankumar7904800]

Cancer Molecular Diagnostics Market

Cancer Molecular Diagnostics Market Size, Share, Trends: Roche Diagnostics Leads

Increasing Acceptance of Liquid Biopsy for Non-Invasive Cancer Detection and Monitoring

Market Overview:

The global Cancer Molecular Diagnostics Market is expected to grow at a CAGR of 12.8% to USD 21.5 billion by 2031, up from USD 8.2 billion in 2022. North America now holds the greatest market share due to its advanced healthcare system and high adoption rates of molecular diagnostics technology. The significant increase in the cancer molecular diagnostics industry is driven by rising cancer incidence worldwide and a growing need for personalised therapy. Early detection and more tailored therapy techniques, made possible by developments in genomic and proteomic technology, have transformed cancer diagnosis. As healthcare professionals increasingly rely on molecular diagnostic technologies to guide therapeutic decisions and enhance patient outcomes, the precision oncology market is expanding.

DOWNLOAD FREE SAMPLE

Market Trends:

Liquid biopsy is a non-invasive replacement for traditional tissue biopsies that is changing cancer diagnosis. Finding and analyzing circulating tumor cells, cell-free DNA, and exosomes in blood samples using this less invasive and more reproducible approach of cancer screening, monitoring, and treatment response assessment allows one to Unlike conventional methods, liquid biopsy lets real-time track of tumor development and finds cancer at earlier stages. Liquid biopsy appeals to people as well as medical experts because of its simplicity and frequent testing potential. As research advances and additional liquid biopsy tests get regulatory approval, use of them is expected to expand, hence driving growth in the cancer molecular diagnostics sector.

Market Segmentation:

Now leading tool in cancer molecular diagnostics is Next-Generation Sequencing (NGS), which changes genomic profile and allows comprehensive simultaneous study of many genes. NGS allows single test detection of multiple genetic alterations including mutations, copy number variations, and gene fusions using unequaled depth and breadth of genomic data. This all-encompassing approach is very crucial in complex cancers where various genetic factors might affect disease progression and therapy response. Driven by its ability to provide a more comprehensive picture of the genetic landscape of a tumor, NGS is a vital instrument in precision oncology and thus rules the market.

Market Key Players:

The cancer molecular diagnostics market is highly competitive, with major players focusing on growing their test portfolios, raising test sensitivity and specificity, and building user-friendly platforms to retain their market position. Key companies such as Roche Diagnostics, Qiagen N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., Abbott Laboratories, Agilent Technologies, Myriad Genetics, Inc., Guardant Health, Exact Sciences Corporation, Natera, Inc., Foundation Medicine (Roche), and Invitae Corporation dominate the market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[willyskristina]

Optometry Equipment Market

Optometry Equipment Market Size, Share, Trends: Carl Zeiss Meditec AG Leads

Integration of AI and Telemedicine in Optometry Equipment Enhances Diagnostic Capabilities

Market Overview:

The Optometry Equipment Market is estimated to grow at a 5.6% CAGR from 2024 to 2031. North America currently dominates the market, accounting for the vast majority of global sales. Key factors include an increase in the prevalence of eye diseases, technological advancements in diagnostic equipment, and increasing awareness of eye health. The industry is quickly developing as the global prevalence of visual issues and eye diseases rises. Technological innovations, such as the introduction of artificial intelligence into diagnostic devices, are propelling the market forward. Furthermore, the growing geriatric population and rising healthcare costs in developing countries are fueling market growth.

DOWNLOAD FREE SAMPLE

Market Trends:

The combination of artificial intelligence (AI) and telemedicine solutions is becoming increasingly common in the optometry equipment business. The increased demand for remote eye care services, as well as the need for more precise and economical diagnostic technology, are driving this development. AI-enabled optometry equipment can evaluate complex eye imaging data, discover minor issues, and provide timely, accurate diagnoses. Telemedicine integration enables remote eye examinations and consultations, improving access to eye care services in underserved areas. Manufacturers are investing heavily in R&D to develop smart optometry equipment that can seamlessly integrate with telemedicine platforms, enhancing patient outcomes and streamlining eye care delivery.

Market Segmentation:

The optical coherence tomography (OCT) systems segment leads the optometry equipment market. OCT technology provides high-resolution cross-sectional imaging of the retina and other eye components, making it a valuable tool for diagnosing and monitoring a wide range of eye problems. Recent developments in OCT technology, such as swept-source OCT and OCT angiography, have expanded these systems' capabilities, enabling more comprehensive imaging of deeper eye structures and blood flow analysis. According to research published in the Journal of Ophthalmology, OCT-based screening found early indications of glaucoma in 15% more cases than traditional techniques, highlighting its clinical value.

Market Key Players:

The optometry equipment sector is highly competitive, with a focus on technological innovation and strategic alliances. Leading companies such as Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co., Ltd., Essilor International S.A., Hoya Corporation, and Alcon, Inc. dominate the market. These firms invest heavily in R&D to diversify their product portfolios and gain a competitive advantage.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[govindtbrc]

Pathology Laboratories Market: Advancements in Diagnostic Services and Technology up to 2033

Market Definition The Pathology Laboratories Market encompasses healthcare facilities dedicated to diagnosing diseases through the examination of patient samples such as blood, urine, tissues, and other body fluids. These labs utilize advanced diagnostic technologies, including molecular, genetic, and biochemical tests, to provide critical insights for the detection, prevention, and treatment of various conditions. Pathology laboratories serve as a vital component in the healthcare continuum, supporting doctors and clinicians with evidence-based diagnoses and therapeutic decisions.

To Know More @ https://www.globalinsightservices.com/reports/pathology-laboratories-market

The global pathology laboratories market is set to expand from $49.8 billion in 2023 to $97.5 billion by 2033, with a robust CAGR of 7.0%.

Market Outlook The Pathology Laboratories Market is witnessing robust growth, driven by rising demand for accurate and timely diagnostic services. With an increasing global burden of chronic diseases like cancer, diabetes, and cardiovascular conditions, there is a heightened need for sophisticated diagnostic tools that can provide early and precise detection. Furthermore, the emergence of personalized medicine and the advancement in diagnostic technologies are transforming the landscape of pathology laboratories, making them indispensable in modern medical practice.

One of the key trends reshaping the market is the integration of artificial intelligence (AI) and machine learning (ML) into pathology. These technologies are being used to enhance the accuracy and efficiency of diagnostic processes, from image analysis to data interpretation. AI-powered solutions help pathologists analyze large datasets rapidly, reducing the likelihood of human error and enabling faster reporting times. As a result, pathology laboratories are becoming more efficient, which is crucial for managing the increasing volume of patient samples.

The shift towards digital pathology is another significant trend impacting the market. By digitizing slides and using digital tools for analysis and storage, pathology labs can streamline workflows, facilitate remote consultations, and improve collaboration among healthcare professionals. Digital pathology is particularly beneficial in the current era of telemedicine and remote healthcare, allowing for continuity of care even when in-person consultations are not possible.

The market is also being shaped by advancements in molecular and genetic testing. With the growing understanding of the genetic basis of diseases, there is a rising demand for pathology services that can provide genetic and genomic analyses. These tests are essential for the diagnosis of complex diseases, such as various types of cancer, and for tailoring treatments to individual patients’ genetic profiles. Consequently, pathology laboratories are investing heavily in next-generation sequencing (NGS) technologies and other cutting-edge diagnostic tools.

An increasing focus on preventive healthcare is another factor contributing to the market’s growth. Governments and healthcare organizations worldwide are emphasizing early disease detection and preventive measures, driving demand for routine pathology tests and screenings. Additionally, the expansion of healthcare infrastructure in developing regions is opening new opportunities for pathology service providers, with governments investing in the establishment of diagnostic centers to meet the needs of growing populations.

Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS32441

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request For Report Customization @ https://www.globalinsightservices.com/request-customization/GIS32441

Market Segmentation

In 2023, the pathology laboratories market exhibited a robust volume, with a projection to grow substantially over the next decade. The clinical pathology segment dominates the market with a 55% share, driven by its extensive application in disease diagnosis and management. Anatomical pathology follows with a 30% share, reflecting its critical role in cancer diagnostics. The molecular pathology segment, although smaller at 15%, is rapidly expanding due to advances in genetic testing and personalized medicine. This growth trajectory is supported by increasing healthcare expenditure and technological advancements in diagnostic tools.

The competitive landscape is characterized by key players such as Quest Diagnostics, LabCorp, and Sonic Healthcare, who are leveraging strategic partnerships and acquisitions to enhance their market positions. Regulatory frameworks, particularly those established by the FDA and European Medicines Agency, significantly impact market dynamics by setting compliance standards that drive innovation and quality. Future projections indicate a promising outlook, with a 10% annual growth rate anticipated, fueled by rising demand for early disease detection and precision medicine. The integration of artificial intelligence and machine learning in diagnostic processes is expected to further revolutionize the market, offering enhanced accuracy and efficiency in pathology services.

Major Players

Sonic Healthcare

Eurofins Scientific

Quest Diagnostics

Laboratory Corporation of America

Unilabs

BioReference Laboratories

ARUP Laboratories

Synlab

Cerba Healthcare

ACM Global Laboratories

Genomic Health

PathGroup

Clinical Reference Laboratory

Labco

MedLabs Diagnostics

KingMed Diagnostics

Al Borg Medical Laboratories

Metropolis Healthcare

InVitro

Amedes

Request For Discounted Pricing @ https://www.globalinsightservices.com/request-special-pricing/GIS32441

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis

For In-Depth Competitive Analysis, Buy Now @ https://www.globalinsightservices.com/checkout/single_user/GIS32441

About Us

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[global-research-report]

Trends in the Laboratory Centrifuges Market

The global laboratory centrifuges market size was estimated at USD 1.73 billion in 2023 and is projected to grow at a CAGR of 5.70% from 2024 to 2030 due to advancements in application and increased research activities. Laboratory centrifuge is essential in separating mixtures based on density, making them crucial in various fields such as biotechnology, pharmaceuticals, and clinical diagnostics.

The increasing demand for personalized medicine and advancements in genomics and proteomics is anticipated to fuel the demand for centrifuge equipment. Moreover, the rise in the prevalence of chronic diseases, growing diagnostic testing, and increasing developments of advanced products are anticipated to propel the market growth in the coming years. For instance, in February 2022, Beckman Coulter Life Sciences introduced the Allegra V-15R Benchtop Centrifuge. This new model has ten rotor configurations and 50 programmable runs, complemented by a wide range of adapters. Its versatile design enables a variety of workflows and model types, including blood separation and high-throughput screening.

Furthermore, technological advancements are anticipated to influence the laboratory centrifuges market over the forecast period. Innovations such as automated and high-speed centrifuges have improved efficiency and accuracy, which are critical in laboratory settings. The development of compact and user-friendly models has also made these devices more accessible to smaller labs and research facilities. For instance, in April 2021, Eppendorf launched the Centrifuge 5910 Ri, a new model designed to boost laboratory efficiency. This centrifuge offers scientists advanced features to streamline and expedite their workflow. Its innovative touchscreen interface allows for rapid parameter settings, while three levels of user management options enhance security and traceability. Such technological advancements and novel developments are anticipated to drive the laboratory centrifuges market.

Laboratory Centrifuges Market Segment Highlights

The equipment segment held the largest share of 82.63% in 2023, driven by advancements in technology and the growing focus of key industry participants on developing novel equipment. 

The floor-standing centrifuge segment held the largest share of 54.88% in 2023, driven by advancements in technology and continuous innovation. 

The clinical centrifuge segment dominated the market with a share of 45.78% in 2023. The clinical centrifuge market is a rapidly growing sector of the healthcare industry, driven by the increasing demand for accurate and efficient diagnostic testing in hospitals, research laboratories, and clinical settings.

The microbiology segment held the largest share of 34.3% in 2023. Due to the growing need for rapid and accurate detection of microorganisms in various applications such as clinical diagnostics, pharmaceutical research, and food safety testing. 

Global Laboratory Centrifuges Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the laboratory centrifuges market report on the basis of product, intended use, application, model, and region.

Product Outlook (Revenue, USD Million, 2018 - 2030)

Equipment

Accessories

Model Outlook (Revenue, USD Million, 2018 - 2030)

Floor-Standing Centrifuges

Benchtop Centrifuges

Intended Use Outlook (Revenue, USD Million, 2018 - 2030)

Clinical Centrifuges

Preclinical Centrifuges

General Purpose Centrifuges

Application Outlook (Revenue, USD Million, 2018 - 2030)

Microbiology

Cellomics

Proteomics

Diagnostics

Genomics

Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Argentina

Brazil

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Order a free sample PDF of the Laboratory Centrifuges Market Intelligence Study, published by Grand View Research.

[dtgmarketreport]

Blood Bank Market Size & Forecast 2025-2035

The global Blood Bank market, estimated to be valued at USD 21.85 billion in 2024, is estimated to grow up to USD 41.05 billion by 2035 with a CAGR of 5.9% in the period from 2025 to 2035. This market will encompass a wide variety of services, including umbilical cord blood-based stem cell banking, therapies collected through plasma collection, and platelet apheresis for cancer patients.

Blood banks handle critical functions like blood typing, cross-matching for transfusion compatibility, and pathogen testing for safety. These facilities are critical for the collection, processing, storage, and distribution of blood and its components, making them crucial for healthcare by ensuring a steady and safe supply of blood for transfusions and other medical procedures.

Market Dynamics

Mobile Blood Donation units increase mobilization

Mobile blood donation units are changing the face of blood donation. They have been going to schools, workplaces, and community events, where people can donate blood conveniently. With this increased access, blood donation rates are particularly increasing for younger generations. Mobile units also involve the community by partnering with organizations and businesses within the same area, often offering incentives to drive up participation. According to research, mHealth applications can boost donation appointment rates by as much as 22.7%. This could save hundreds of thousands of lives every year.

Challenges of Short Shelf Life for Blood Products

The blood products do have a short shelf life; for example, whole blood only remains available up to 42 days. For platelets, however, they are only available from 5-7 days, thereby presenting a huge problem for inventory control. Most blood remains unutilized and its potential to cause pressure on management concerning collection, donations, and not going about scarce at all times.

AI-Enhanced Blood Management Solutions

Artificial Intelligence and data analytics become indispensable tools in blood management. These technologies help blood banks understand their inventory better, predict donation trends, and optimize donor outreach. Predictive analytics can predict what blood will be needed by whom, thereby reducing short shelf life waste and making donors retain themselves for long periods of time, so that a more reliable blood supply can be ensured.

Expert opinions

According to Robert Scanlon, the head of Blood Bank of Alaska, one of the great successes of mobile drives has been local donations as it has saved lives state-wide.

Kate Fry, the CEO of America's Blood Centers, also spoke about her work on leadership development with Vanderbilt University.

Get A Free Sample Report @Click Here

Market Segmentation

Product Type

The Blood Bank market carries the entire spectrum of blood products for transfusion such as whole blood, red blood cells (RBCs), platelets, plasma, cryoprecipitate, and white blood cells. Due to its essential role in transportation, RBC is primarily the most transfused form of blood product. Longer the shelf life of the products of RBC it easy for handling within blood bank sites as compared to any of other blood products.

Function Type

The major activities of blood banking include collection, processing, transportation, storage, and testing. Testing is the most essential as it ensures that products meant for transfusions are safe and compatible. In the screening procedure, for instance, it involves conducting tests on infectious diseases together with finding out the different blood types to match up the donors with recipients safely.

Regional Analysis

North America : is the largest market in the global blood bank market due to its advanced healthcare infrastructure, stringent safety standards, and the presence of well-established organizations, such as the American Red Cross. Blood centers in this region supply blood products to over 150 million people and serve more than 3,500 hospitals.

Asia-Pacific: The most booming market is that of the Asia-Pacific region, which is driven by enhanced health care spending, growing blood donation awareness, and government programs oriented toward improving blood safety. The countries of China and India are expanding their services of blood banking, therefore greatly contributing to the quick growth experienced in the region. Competitive Environment The Blood Bank market is also highly competitive. Major players are involved in research and development to improve their position. The key players operating in the market are: The American Red Cross NHS Blood and Transplant Canadian Blood Services Vitalant America's Blood Centers Recent development includes a partnership between InVita Healthcare Technologies and BloodHub to enhance blood supply chain automation and Roche's FDA-approved malaria test to screen blood donors in the U.S. Recent Developments March 2024: Roche won the approval from the FDA to use its malaria test for blood donors to boost safety. InVita Healthcare Technologies and BloodHub recently formed a partnership to advance blood management systems in North America.

Conclusion :

 The Blood Bank market is undergoing evolution, characterized by advancements in mobile donation, artificial intelligence, and blood management technologies. Notwithstanding challenges such as the limited shelf lives of blood products, the growth prospects of the market remain robust, propelled by innovations in blood collection, testing, and distribution. North America continues to dominate the market; conversely, the Asia-Pacific region presents substantial growth opportunities. Additionally, the expansion of the market is further enhanced by the rising demand for blood products and government initiatives aimed at improving blood safety on a global scale.

[industrynewsupdates]

Blood Screening Market Key Companies, Growth and Forecast Report, 2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030. 

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

Blood Screening Market worth $3.4 billion by 2028

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

Download an Illustrative overview:

Browse in-depth TOC on "Blood Screening Market"

189 - Tables

45 - Figures

220 – Pages

The Reagents & Kits segment is expected to account for the largest share in 2022.

Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.

Nucleic Acid Test segment aimed the highest share during the forecast period

The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.

North America has the upper hand in the global Blood screening market

By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.

Request Sample Pages:

Blood Screening Market Dynamics:

Drivers:

Increasing number of blood donations worldwide

Restraints:

Alternative technologies

Opportunities:

Emerging markets

Challenge:

High cost of blood screening technologies

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France),  Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Recent Developments:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Inquiry Before Buying:

Blood Screening Market Advantages:

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Related Reports:

[hariganesh858]

Phenylketonuria Treatment Market

Phenylketonuria Treatment Market Size, Share, Trends: BioMarin Pharmaceutical Inc. Leads

Rising adoption of enzyme replacement therapies drives market growth

Market Overview: 

The global Phenylketonuria Treatment Market is projected to grow at a CAGR of 8.5% during the forecast period from 2024 to 2031. North America dominates this market, accounting for approximately 40% of the global market share. Key metrics include the increasing prevalence of phenylketonuria, rising awareness about early diagnosis and treatment, and the development of novel therapies.

The phenylketonuria treatment market is steadily developing, owing to reasons such as increased emphasis on newborn screening programs, the availability of viable treatment alternatives, and increased investment in research and development efforts. The introduction of enzyme replacement medicines and the development of gene therapy techniques are accelerating market expansion.

DOWNLOAD FREE SAMPLE

Market Trends: 

The phenylketonuria treatment market is shifting significantly towards enzyme replacement therapies, which seek to replace the defective phenylalanine hydroxylase (PAH) enzyme and lower blood phenylalanine levels. The US FDA's approval of Palynziq (pegvaliase) in 2018 marked a significant milestone in the treatment of phenylketonuria, providing a unique therapy option for adult patients with uncontrolled blood phenylalanine levels.

According to industry analysis, the usage of enzyme substitution therapy has increased by 25% in the last three years, owing to their potential to improve metabolic management and minimize the burden of dietary restrictions. Enzyme substitution therapies will account for more than half of the entire phenylketonuria therapy market by 2030, as more patients and healthcare professionals learn about their benefits.

Market Segmentation: 

The Kuvan segment dominates the phenylketonuria treatment market, accounting for over 50% of the market share. Kuvan (sapropterin dihydrochloride) is an oral drug that acts as a cofactor for the PAH enzyme, so increasing its activity and decreasing blood phenylalanine levels in responding patients. Kuvan's broad use as a first-line treatment for phenylketonuria, as well as its known efficacy and safety profile, have helped it maintain its dominant market position.

According to our analysis, Kuvan sales have increased by 15% per year over the last five years, owing to an increase in the number of diagnosed patients and expanded indications for usage. The release of generic versions of sapropterin dihydrochloride in several markets is intended to increase the availability and affordability of this therapy.

Market Key Players:

BioMarin Pharmaceutical Inc.

Novartis AG

Homology Medicines, Inc.

Rubius Therapeutics, Inc.

Synlogic, Inc.

Codexis, Inc.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/